MA30922B1 - Anticorps d'agonistes de trkb et leurs utilisations - Google Patents

Anticorps d'agonistes de trkb et leurs utilisations

Info

Publication number
MA30922B1
MA30922B1 MA31923A MA31923A MA30922B1 MA 30922 B1 MA30922 B1 MA 30922B1 MA 31923 A MA31923 A MA 31923A MA 31923 A MA31923 A MA 31923A MA 30922 B1 MA30922 B1 MA 30922B1
Authority
MA
Morocco
Prior art keywords
agonist antibodies
trkb agonist
trkb
antibodies
methods
Prior art date
Application number
MA31923A
Other languages
English (en)
Inventor
Yan Wang
Steven B Cohen
Marc Nasoff
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc filed Critical Irm Llc
Publication of MA30922B1 publication Critical patent/MA30922B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'INVENTION CONCERNE DES AGONISTES D'ANTICORPS DE TRKB ET LEURS PROCÉDÉS D'UTILISATION.
MA31923A 2006-11-09 2009-05-27 Anticorps d'agonistes de trkb et leurs utilisations MA30922B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US85816906P 2006-11-09 2006-11-09

Publications (1)

Publication Number Publication Date
MA30922B1 true MA30922B1 (fr) 2009-11-02

Family

ID=39365312

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31923A MA30922B1 (fr) 2006-11-09 2009-05-27 Anticorps d'agonistes de trkb et leurs utilisations

Country Status (27)

Country Link
US (1) US20100150914A1 (fr)
EP (1) EP2087007A2 (fr)
JP (1) JP2010509354A (fr)
KR (1) KR20090088896A (fr)
CN (1) CN101573381A (fr)
AR (1) AR063640A1 (fr)
AU (1) AU2007316418A1 (fr)
BR (1) BRPI0719000A2 (fr)
CA (1) CA2669205A1 (fr)
CL (1) CL2007003236A1 (fr)
CO (1) CO6180432A2 (fr)
CR (1) CR10779A (fr)
DO (1) DOP2009000102A (fr)
EA (1) EA200970469A1 (fr)
EC (1) ECSP099392A (fr)
IL (1) IL198468A0 (fr)
MA (1) MA30922B1 (fr)
MX (1) MX2009004881A (fr)
NI (1) NI200900081U (fr)
NO (1) NO20092217L (fr)
PE (1) PE20081168A1 (fr)
RU (1) RU2009121641A (fr)
SM (1) SMAP200900040A (fr)
TN (1) TN2009000181A1 (fr)
TW (1) TW200829270A (fr)
WO (1) WO2008058127A2 (fr)
ZA (1) ZA200902943B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101909647A (zh) * 2007-10-23 2010-12-08 诺瓦提斯公司 TrkB抗体用于治疗呼吸病症的用途
US8642035B2 (en) * 2008-01-17 2014-02-04 Irm Llc Anti-TrkB antibodies
WO2010106187A2 (fr) * 2009-03-20 2010-09-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Inhibiteurs de cathepsine s pour la prévention ou le traitement de troubles associés à l'obésité
GB2491106A (en) * 2011-05-18 2012-11-28 Univ Basel Antibodies against tropomyosin-related kinase B receptors
CN104244981A (zh) * 2011-12-09 2014-12-24 诺和诺德A/S Glp-1激动剂
CN102901815B (zh) * 2012-11-05 2014-10-22 武汉远征世纪制药有限公司 一种检测TrkB受体816/817位酪氨酸位点活性的ELISA试剂盒及其使用方法
CN102944674B (zh) * 2012-11-05 2014-10-22 武汉远征世纪制药有限公司 一种检测TrkB受体pan-Tyr位点活性的ELISA试剂盒及其使用方法
EP3143043B1 (fr) 2014-05-16 2022-12-14 Pfizer Inc. Anticorps bispécifiques avec interfaces ch1-cl modifiees
CN104524568B (zh) * 2015-01-08 2018-04-20 中国人民解放军第二军医大学 一种治疗肥胖症的药物组合物及其应用
EP3328898B8 (fr) 2015-07-28 2024-04-10 6452728 Canada Corp. Compositions d'agoniste trkb ou trkc et méthodes de traitement de troubles otiques
WO2017085035A1 (fr) * 2015-11-17 2017-05-26 Glaxosmithkline Intellectual Property Development Limited Agonistes de liaison utilisés pour le traitement de troubles neurologiques et d'autres troubles
US9914781B1 (en) 2016-11-08 2018-03-13 Glaxosmithkline Intellectual Property Development Limited Binding agonist for treatment of neurological and other disorders
AU2018255244A1 (en) 2017-04-21 2019-10-31 Mellitus, Llc Methods and antibodies for diabetes-related applications
US10793634B2 (en) 2017-06-09 2020-10-06 Boehringer Ingelheim International Gmbh Anti-TrkB antibodies
MA51207A (fr) 2017-11-30 2020-10-07 Regeneron Pharma Anticorps monoclonaux anti-trkb et leurs procédés d'utilisation
CN112272677A (zh) 2018-02-26 2021-01-26 米纳瓦生物技术公司 使用抗muc1＊抗体的诊断方法
CN110818797B (zh) * 2018-08-09 2022-11-04 东莞市朋志生物科技有限公司 一种抗人ca153蛋白的重组抗体
TW202233668A (zh) 2020-10-21 2022-09-01 德商百靈佳殷格翰國際股份有限公司 用於治療眼部疾病之雙特異性抗-VEGF及抗-TrkB結合分子
WO2023125485A1 (fr) * 2021-12-28 2023-07-06 4B Technologies (Beijing) Co., Limited Anticorps trkb et son application

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0768377A1 (fr) 1988-09-02 1997-04-16 Protein Engineering Corporation Production et sélection de protéines de liaison diversifiées de recombinaison
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2108147C (fr) 1991-04-10 2009-01-06 Angray Kang Banques de recepteurs heterodimeriques construites a l'aide de phagemides
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
EP0733070A1 (fr) 1993-12-08 1996-09-25 Genzyme Corporation Procede de generation d'anticorps specifiques
ES2247204T3 (es) 1994-01-31 2006-03-01 Trustees Of Boston University Bancos de anticuerpos policlonales.
US5601820A (en) * 1994-07-07 1997-02-11 Children's Hospital Of Philadelphia Compositions and methods of making and using human full length TRK-B
CA2610771A1 (fr) * 2005-06-06 2006-12-14 Wyeth Anticorps monoclonaux anti-trkb et utilisations de ceux-ci
AU2007210862A1 (en) * 2006-02-02 2007-08-09 Rinat Neuroscience Corp. Methods for treating unwanted weight loss or eating disorders by administering a trkB agonist
JP2009525319A (ja) * 2006-02-02 2009-07-09 ライナット ニューロサイエンス コーポレイション ｔｒｋＢアンタゴニストを投与することにより肥満を治療する方法

Also Published As

Publication number Publication date
AR063640A1 (es) 2009-02-04
IL198468A0 (en) 2011-08-01
BRPI0719000A2 (pt) 2013-12-10
WO2008058127A3 (fr) 2008-10-02
CR10779A (es) 2009-07-03
PE20081168A1 (es) 2008-09-22
US20100150914A1 (en) 2010-06-17
TN2009000181A1 (en) 2010-10-18
CL2007003236A1 (es) 2008-06-13
CN101573381A (zh) 2009-11-04
WO2008058127A9 (fr) 2008-08-21
ECSP099392A (es) 2009-07-31
MX2009004881A (es) 2009-05-21
TW200829270A (en) 2008-07-16
AU2007316418A1 (en) 2008-05-15
RU2009121641A (ru) 2010-12-20
CA2669205A1 (fr) 2008-05-15
SMAP200900040A (it) 2010-01-19
WO2008058127A2 (fr) 2008-05-15
NI200900081U (es) 2010-03-16
DOP2009000102A (es) 2010-10-31
ZA200902943B (en) 2010-05-26
EP2087007A2 (fr) 2009-08-12
EA200970469A1 (ru) 2010-04-30
NO20092217L (no) 2009-06-09
CO6180432A2 (es) 2010-07-19
JP2010509354A (ja) 2010-03-25
KR20090088896A (ko) 2009-08-20

Similar Documents

Publication Publication Date Title
MA30922B1 (fr) Anticorps d'agonistes de trkb et leurs utilisations
MA30910B1 (fr) Anticorps et immunoconjugues, et leurs utilisations
MA32535B1 (fr) Compositions et procédés pour des anticorps ciblant une protéine du complément c5
MA30153B1 (fr) Anticorps anti-ox40l et methodes correspondantes
MA30497B1 (fr) Anticorps et immunco-conjugues, et leurs utilisations.
MA31502B1 (fr) Anticorps anti-notch 1 specifiques a nrr et ses procedes d'utilisation
MA30945B1 (fr) Anticorps anti-tat226 et immunoconjugués
MA29528B1 (fr) Agents de fixation
MA31231B1 (fr) Anticorps anti-robo4 et utilisations de ceux-ci
NO20083397L (no) Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse
FR15C0048I2 (fr) Anticorps antagonistes de il-17
MA33256B1 (fr) Anticorps et immunoconjugués anti-fcrh5 et procédés d'utilisation
MA34749B1 (fr) Anticorps anti-récepteur de la barrière hémato-encéphalique à faible affinité et leurs utilisations
MA34818B1 (fr) Anticorps anti-pcsk9 et procédés d'utilisation
MA30531B1 (fr) Anticorps anti-dll4 et leurs procedes d'utilisation
EA200702193A1 (ru) Гликозилирование белков
CL2008002885A1 (es) Anticuerpo anti-receptor de interleucina-6 (il-6); y composicion farmaceutica que lo comprende
PA8850201A1 (es) Combinaciones antitumorales que contienen anticuerpos
HN2006015949A (es) Anticuerpos de p-caderina
MA35009B1 (fr) Cristaux d'anticorps anti-sclérotine et formulations de ceux-ci
PA8849901A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen específicamente cd38 y la citarabina
DE602006015793D1 (de) Proteolipidmembran und lipidmembranen-biosensor
MA29369B1 (fr) Dosage fixe d'anticorps anti-her
PA8850101A1 (es) Combinaciones antitumorales que contienen anticuerpos
MA30128B1 (fr) Combinaisons pharmaceutiques d'un antagoniste de receptuer d'angiotensine et d'un inhibiteur de nep